Clinical pharmacological study of a plasma-derived factor VIIa and factor X mixture (MC710) in haemophilia patients with inhibitors - Phase I trial

Haemophilia

Volumn 18, Issue 1, 2012, Pages 94-101

  Shirahata, A ^a   Fukutake, K ^b   Mimaya, J ^c   Takamatsu, J ^d   Shima, M ^e   Hanabusa, H ^f   Takedani, H ^g   Takashima, Y ^c   Matsushita, T ^h   Tawa, A ⁱ   Higasa, S ^j   Takata, N ^k   Sakai, M ^a   Kawakami, K ^l   Ohashi, Y ^g   Saito, H ^m  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c SHIZUOKA CHILDREN'S HOSPITAL   (Japan)

^d NAGOYA UNIVERSITY HOSPITAL   (Japan)

^e NARA MEDICAL UNIVERSITY   (Japan)

^f Ogikubo Hospital   (Japan)

^g UNIVERSITY OF TOKYO   (Japan)

^h NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ OSAKA NATIONAL HOSPITAL   (Japan)

^j HYOGO COLLEGE OF MEDICINE   (Japan)

^k HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^l Kagoshima City Hospital   (Japan)

^m NAGOYA CENTRAL HOSPITAL   (Japan)

more..

Author keywords

Bypassing agents; Factor VIIa; Factor X; Haemophilia; Inhibitors; PK PD

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7A; MC 710; RECOMBINANT BLOOD CLOTTING FACTOR 7A; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DOSE ESCALATION; DRUG INDUCED HEADACHE; DRUG SAFETY; HEMOPHILIA A; HEMOPHILIA B; HERPETIC STOMATITIS; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; OPEN STUDY; PARTIAL THROMBOPLASTIN TIME; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADOLESCENT; ADULT; AREA UNDER CURVE; BLOOD COAGULATION; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FACTOR VIIA; FACTOR X; HEMOPHILIA A; HUMANS; MALE; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; YOUNG ADULT;

EID: 84355162288     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02548.x     Document Type: Article

References (15)

1. Schneiderman J, Rubin E, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience. Haemophilia 2007; 13: 244-8.
2. Economou M, Teli A, Tzantzaroudi A, Tsatra I, Zavitsanakis A, Athanassiou-Metaxa M. Sequential therapy with activated prothrombin complex concentrate (FEIBA) and recombinant factor VIIa in a patient with severe haemophilia A, inhibitor presence and refractory bleeding. Haemophilia 2008; 14: 390-1.
3. Livnat T, Martinowitz U, Zivelin A, Seligsohn U. Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma. Haemophilia 2008; 14: 782-6.
4. Møss J, Scharling B, Ezban M, Møller Sørensen T. Evaluation of the safety and pharmacokinetics of a fast-acting recombinant FVIIa analogue, NN1731, in healthy male subjects. J Thromb Haemost 2009; 7: 299-305.
5. Stennicke HR, Ostergaard H, Bayer RJ et al. Generation and biochemical characterization of glycoPEGylated factor VIIa derivatives. Thromb Haemost 2008; 100: 920-8.
6. Hartmann R, Dockal M, Kammlander W et al. Factor IX mutants with enhanced catalytic activity. J Thromb Haemost 2009; 7: 1656-62.
7. Nakatomi Y, Nakashima T, Gokudan S et al. Combining FVIIa and FX into a mixture which imparts a unique thrombin generation potential to hemophilic plasma: an in vitro assessment of FVIIa/FX mixture as an alternative bypassing agent. Thromb Res 2010; 125: 457-63.
8. Komiyama Y, Pedersen AH, Kisiel W. Proteolytic activation of human factors IX and X by recombinant human factor VIIa: effects of calcium, phospholipide and tissue factors. Biochemistry 1990; 29: 9418-25.
9. Tomokiyo K, Nakatomi Y, Araki T et al. A novel therapeutic approach combining human plasma-derived factors VIIa and X for haemophilia patients with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with factor VIIa alone. Vox Sang 2003; 85: 290-9.
10. Hedner U. Dosing with recombinant factor VIIa based on current evidence. Semin Hematol 2004; 41(Suppl. 1): 35-9.
11. Lindley CM, Sawyer WT, Macik BG et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994; 55: 638-48.
12. Mori K, Sakai H, Nakano N et al. Congenital factor X deficiency in Japan. Tohoku J Exp Med 1981; 133: 1-19.
13. Ostermann H, Haertel S, Knaub S, Kalina U, Jung K, Pabinger I. Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers. Thromb Haemost 2007; 98: 790-7.
14. Shirahata A, Kamiya T, Takamatsu J et al. Clinical trial to investigate the pharmacokinetics, pharmacodynamics, safety, and efficacy of recombinant factor VIIa in Japanese patients with haemophilia with inhibitors. Int J Hematol 2001; 73: 517-25.
15. Elg M, Carlsson S, Gustafsson D. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. Thromb Res 2001; 101: 145-57.